Zimycan "Not Approvable" Letter Could Mean One-Year Delay In Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's concerns stem from Barrier Therapeutics' use of a different grade of petrolatum in the absorption study than in clinical trials for the diaper dermatitis agent. The firm says conducting an additional study would take two to four months, plus six months for an agency review.
You may also be interested in...
Barrier Submits “Complete Response” For The Drug Formerly Known As Zimycan
Submission of supplemental information on the antifungal puts the review deadline in mid-February, the firm says.
Barrier Submits “Complete Response” For The Drug Formerly Known As Zimycan
Submission of supplemental information on the antifungal puts the review deadline in mid-February, the firm says.
OTC-To-Rx Switch: Barrier Expects Zimycan Trial Data To Boost NDA
Barrier Therapeutics expects to amend Zimycan NDA with Phase III study in Candida-associated diaper dermatitis by year-end. Firm hopes to revive Johnson & Johnson’s attempted OTC topical antifungal as sole prescription option.